Precision testing strategy strongly benefits stable patients with suspected CAD

CHICAGO — In stable symptomatic patients with suspected CAD, a precision testing strategy was linked to a 70% reduction in death, MI or catheterization without obstructive CAD at 1 year compared with the usual testing, researchers reported.For the PRECISE trial, presented at the American Heart Association Scientific Sessions, Pamela S. Douglas, MD, MACC, FASE, FAHA, Ursula Geller Professor

Related Keywords

United States ,Chicago ,Illinois ,American ,Julia Indik ,Pamelas Douglas ,American Heart Association ,American College Of Cardiology ,Cardiovascular Diseases At Duke University ,American Heart Association Scientific Sessions ,Heart Disease Research ,Ursula Geller Professor Of Research ,University Of Arizona College Medicine ,Flinn Foundation ,Ursula Geller Professor ,Cardiovascular Diseases ,Duke University ,American College ,Risk Score ,American Heart Association Endowed Chair ,Arizona College ,Multisociety Guideline ,Chest Pain ,